isoxazoles has been researched along with Colitis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejak, V; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; El Bakali, J; Lambert, DM; Leleu-Chavain, N; Lemaire, L; Lemoine, A; Mansouri, R; Millet, R; Muccioli, GG; Renault, N; Rigo, B; Tourteau, A | 1 |
| Andrzejak, V; Barczyk, A; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; Leleu-Chavain, N; Millet, R; Rigo, B; Tourteau, A | 1 |
| Hasumi, K; Kato, JY; Ohta, S; Saito, T; Sato, J; Sato, S; Shirota, K; Suzuki, H | 1 |
| Akbarali, HI; AlSharari, SD; Bagdas, D; Cabral, GA; Carroll, FI; Damaj, MI; Lichtman, PA; McGee, EA; Raborn, ES | 1 |
| Do, A; Fairlie, DP; Iyer, A; Lohman, RJ; Reid, RC; Sweet, MJ | 1 |
| Agarwal, G; B-Rao, C; Balachandran, S; Bhatt, P; Bose, J; Chetrapal-Kunwar, A; Dadarkar, SS; Dagia, NM; Fonseca, L; Gadekar, PK; Gupte, RD; Kamath, DV; Mandrekar, N; Pari, K; Parkale, SS; Rodge, AH; Sharma, S; Srinivasan, S; Vishwakarma, RA | 1 |
| Andrzejak, V; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; El Bakali, J; Lambert, DM; Millet, R; Muccioli, GG; Renault, N | 1 |
| Vandooren, AK; Verschueren, P; Westhovens, R | 1 |
| Bond, J; Finn, S; McCarthy, D; Quinn, C; Sheahan, K | 1 |
| Chen, C; Gonzalez, FJ; Haase, VH; Ito, S; Morimura, K; Shah, YM; Yim, SH | 1 |
10 other study(ies) available for isoxazoles and Colitis
| Article | Year |
|---|---|
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.
Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Colitis; Dextran Sulfate; HT29 Cells; Humans; Interleukin-1beta; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2013 |
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
Topics: Adamantane; Amidohydrolases; Animals; Anti-Inflammatory Agents; Body Weight; Cannabinoids; Colitis; Disease Models, Animal; Enzyme Inhibitors; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2014 |
Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept.
Topics: Animals; Binding Sites; Cell Line; Colitis; Drug Design; Female; Half-Life; Humans; Isoxazoles; Liver; Male; Mice, Inbred BALB C; Molecular Docking Simulation; p38 Mitogen-Activated Protein Kinases; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2014 |
Sex Differences and Drug Dose Influence the Role of the α7 Nicotinic Acetylcholine Receptor in the Mouse Dextran Sodium Sulfate-Induced Colitis Model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Bridged Bicyclo Compounds, Heterocyclic; Colitis; Dextran Sulfate; Disease Models, Animal; Female; Inflammation; Isoxazoles; Male; Mice; Mice, Knockout; Phenylurea Compounds; Quinuclidines | 2017 |
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
Topics: Animals; B-Lymphocytes; Colitis; Colon; Cytokines; Dextran Sulfate; Diarrhea; Female; Hemorrhage; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Intestinal Mucosa; Isoxazoles; Lymphocytes; Mice; Mice, Inbred C57BL; Mucins; Myeloid Cells; Neutrophil Activation; Peroxidase | 2017 |
A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cell Line; Colitis; Dextran Sulfate; Disease Models, Animal; Drug Delivery Systems; Humans; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Mice; Mice, Inbred C57BL; Monocytes; Quinolines | 2009 |
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
Topics: Amidohydrolases; Animals; Colitis; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Isoxazoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure | 2011 |
Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy; Colitis; Colon; Colonoscopy; Diagnosis, Differential; Diarrhea; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Isoxazoles; Leflunomide; Middle Aged; Weight Loss | 2005 |
Angioinvasive aspergillosis presenting as neutropenic colitis.
Topics: Adalimumab; Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Aspergillosis; Cholecystectomy; Colitis; Colon; Diagnosis, Differential; Female; Hernia, Abdominal; Humans; Immunocompromised Host; Isoxazoles; Leflunomide; Pancytopenia; Rheumatic Diseases | 2006 |
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade.
Topics: Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix-Loop-Helix Transcription Factors; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation Mediators; Integrases; Intestinal Mucosa; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Mice; Mice, Transgenic; Recombination, Genetic; Signal Transduction; Time Factors; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |